171 related articles for article (PubMed ID: 34248990)
1. Interleukin-1- Receptor Kinase 4 Inhibition: Achieving Immunomodulatory Synergy to Mitigate the Impact of COVID-19.
Gupta A; Chun HJ
Front Immunol; 2021; 12():693085. PubMed ID: 34248990
[No Abstract] [Full Text] [Related]
2. Involvement of Interleukin-1 Receptor-Associated Kinase 4 and Interferon Regulatory Factor 5 in the Immunopathogenesis of SARS-CoV-2 Infection: Implications for the Treatment of COVID-19.
Stoy N
Front Immunol; 2021; 12():638446. PubMed ID: 33936053
[TBL] [Abstract][Full Text] [Related]
3. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome.
Du P; Geng J; Wang F; Chen X; Huang Z; Wang Y
Int J Med Sci; 2021; 18(6):1356-1362. PubMed ID: 33628091
[TBL] [Abstract][Full Text] [Related]
4. Cytokine "storm", cytokine "breeze", or both in COVID-19?
Lippi G; Plebani M
Clin Chem Lab Med; 2020 Dec; 59(4):637-639. PubMed ID: 33554554
[No Abstract] [Full Text] [Related]
5. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
[TBL] [Abstract][Full Text] [Related]
6. Blocking TNF signaling may save lives in COVID-19 infection.
Ablamunits V; Lepsy C
Mol Biol Rep; 2022 Mar; 49(3):2303-2309. PubMed ID: 35076845
[TBL] [Abstract][Full Text] [Related]
7. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.
Al-Kuraishy HM; Al-Gareeb AI; Mostafa-Hedeab G; Kasozi KI; Zirintunda G; Aslam A; Allahyani M; Welburn SC; Batiha GE
Front Immunol; 2021; 12():749291. PubMed ID: 34867978
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2/ACE2 Interaction Suppresses IRAK-M Expression and Promotes Pro-Inflammatory Cytokine Production in Macrophages.
Pantazi I; Al-Qahtani AA; Alhamlan FS; Alothaid H; Matou-Nasri S; Sourvinos G; Vergadi E; Tsatsanis C
Front Immunol; 2021; 12():683800. PubMed ID: 34248968
[TBL] [Abstract][Full Text] [Related]
9. CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma.
Geng J; Chen L; Yuan Y; Wang K; Wang Y; Qin C; Wu G; Chen R; Zhang Z; Wei D; Du P; Zhang J; Lin P; Zhang K; Deng Y; Xu K; Liu J; Sun X; Guo T; Yang X; Wu J; Jiang J; Li L; Zhang K; Wang Z; Zhang J; Yan Q; Zhu H; Zheng Z; Miao J; Fu X; Yang F; Chen X; Tang H; Zhang Y; Shi Y; Zhu Y; Pei Z; Huo F; Liang X; Wang Y; Wang Q; Xie W; Li Y; Shi M; Bian H; Zhu P; Chen ZN
Signal Transduct Target Ther; 2021 Sep; 6(1):347. PubMed ID: 34564690
[TBL] [Abstract][Full Text] [Related]
10. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
Miao Y; Fan L; Li JY
Front Immunol; 2020; 11():1445. PubMed ID: 32612616
[No Abstract] [Full Text] [Related]
11. A comprehensive review on sarilumab in COVID-19.
Khiali S; Rezagholizadeh A; Entezari-Maleki T
Expert Opin Biol Ther; 2021 May; 21(5):615-626. PubMed ID: 33161757
[No Abstract] [Full Text] [Related]
12. Immunomodulatory Drugs in the Management of SARS-CoV-2.
Burrage DR; Koushesh S; Sofat N
Front Immunol; 2020; 11():1844. PubMed ID: 32903555
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4.
Onodi F; Bonnet-Madin L; Meertens L; Karpf L; Poirot J; Zhang SY; Picard C; Puel A; Jouanguy E; Zhang Q; Le Goff J; Molina JM; Delaugerre C; Casanova JL; Amara A; Soumelis V
J Exp Med; 2021 Apr; 218(4):. PubMed ID: 33533916
[TBL] [Abstract][Full Text] [Related]
14. The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19.
Ali A; Kamjani MH; Kesselman MM
Recent Pat Antiinfect Drug Discov; 2020; 15(2):104-112. PubMed ID: 32962623
[TBL] [Abstract][Full Text] [Related]
15. Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i).
Pinheiro MM; Fabbri A; Infante M
Immunotherapy; 2021 Jun; 13(9):753-765. PubMed ID: 33906375
[TBL] [Abstract][Full Text] [Related]
16. Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality.
Moradian N; Gouravani M; Salehi MA; Heidari A; Shafeghat M; Hamblin MR; Rezaei N
Eur Cytokine Netw; 2020 Sep; 31(3):81-93. PubMed ID: 33361013
[TBL] [Abstract][Full Text] [Related]
17. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
Iannaccone G; Scacciavillani R; Del Buono MG; Camilli M; Ronco C; Lavie CJ; Abbate A; Crea F; Massetti M; Aspromonte N
Cardiorenal Med; 2020; 10(5):277-287. PubMed ID: 32599589
[TBL] [Abstract][Full Text] [Related]
18. Macrophage Activation and Cytokine Release Syndrome in COVID-19: Current Updates and Analysis of Repurposed and Investigational Anti-Cytokine Drugs.
Iqubal A; Hoda F; Najmi AK; Haque SE
Drug Res (Stuttg); 2021 Apr; 71(4):173-179. PubMed ID: 33434935
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19.
Geng J; Wang F; Huang Z; Chen X; Wang Y
Cytokine; 2021 Jul; 143():155544. PubMed ID: 33926774
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
Arch Med Res; 2020 Aug; 51(6):595-597. PubMed ID: 32482373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
